Direct healthcare professional communication on the launch of Vibativ®

As a responsible pharmaceutical company, we will be maintaining a pregnancy registry for anyone who is exposed to Vibativ® during pregnancy.
If your patient has been found to be pregnant during treatment with Vibativ®, then we would ask for consent to follow the pregnancy.
Please contact Theravance Biopharma’s Information line for an information pack

Healthcare professional educational pack for Vibativ® (telavancin)

This guide is provided to all prescribers of Vibativ® to give clear instructions for the safe use of the product.

Adverse event reporting

Theravance Biopharma has a regulatory responsibility to monitor the safety of medicines. You can report an adverse event or adverse drug reaction using the form below.

Click here to download the form.